ANB-032

N/A

Report date: 2025/02/15 20:00:08

Base Information

Drug NameANB-032
Drug Alias NameANB-032
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB- and T-lymphocyte attenuator agonists
TargetsB- and T-lymphocyte attenuator
Therapy Area/IndicationsInflammationEczemaDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnaptysbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnaptysbio Inc
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsEczemaDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A